Author:
Jacobsen Paula,Zhong Wei,Xu Rengyi,Nomikos George
Funder
Takeda Pharmaceutical Company
Subject
Psychiatry and Mental health,Clinical Psychology
Reference28 articles.
1. Practice Guideline for the Treatment of Patients With Major Depressive Disorder,2010
2. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder;Bang-Andersen;J. Med. Chem.,2011
3. Review of maintenance trials for major depressive disorder: a 25-year perspective from the US Food and Drug Administration;Borges;J. Clin. Psychiatry,2014
4. A randomized clinical study of LU AA21004 in the prevention of relapse in patients with major depressive disorder;Boulenger;J. Psychopharmacol.,2012
5. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder;Boulenger;Int. Clin. Psychopharmacol.,2014
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献